SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Fundamental Analysis & Valuation

FRA:1SXP • DE000A3ENQ51

Current stock price

13.76 EUR
+0.04 (+0.29%)
Last:

This 1SXP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. 1SXP.DE Profitability Analysis

1.1 Basic Checks

  • 1SXP had positive earnings in the past year.
  • 1SXP had a positive operating cash flow in the past year.
  • 1SXP had positive earnings in each of the past 5 years.
  • Each year in the past 5 years 1SXP had a positive operating cash flow.
1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCF1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

1.2 Ratios

  • The Return On Assets of 1SXP (9.26%) is better than 80.95% of its industry peers.
  • 1SXP's Return On Equity of 16.21% is amongst the best of the industry. 1SXP outperforms 85.71% of its industry peers.
  • 1SXP's Return On Invested Capital of 12.84% is amongst the best of the industry. 1SXP outperforms 85.71% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for 1SXP is in line with the industry average of 12.74%.
Industry RankSector Rank
ROA 9.26%
ROE 16.21%
ROIC 12.84%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1SXP.DE Yearly ROA, ROE, ROIC1SXP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • The Profit Margin of 1SXP (15.13%) is better than 76.19% of its industry peers.
  • 1SXP's Profit Margin has improved in the last couple of years.
  • 1SXP has a Operating Margin of 19.08%. This is in the better half of the industry: 1SXP outperforms 76.19% of its industry peers.
  • 1SXP's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 33.68%, 1SXP is in line with its industry, outperforming 42.86% of the companies in the same industry.
  • 1SXP's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 19.08%
PM (TTM) 15.13%
GM 33.68%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
1SXP.DE Yearly Profit, Operating, Gross Margins1SXP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. 1SXP.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1SXP is creating some value.
  • Compared to 1 year ago, 1SXP has about the same amount of shares outstanding.
  • 1SXP has about the same amout of shares outstanding than it did 5 years ago.
  • The debt/assets ratio for 1SXP has been reduced compared to a year ago.
1SXP.DE Yearly Shares Outstanding1SXP.DE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Yearly Total Debt VS Total Assets1SXP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • The Debt to FCF ratio of 1SXP is 7.05, which is on the high side as it means it would take 1SXP, 7.05 years of fcf income to pay off all of its debts.
  • 1SXP has a better Debt to FCF ratio (7.05) than 61.90% of its industry peers.
  • 1SXP has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of 1SXP (0.08) is better than 90.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 7.05
Altman-Z N/A
ROIC/WACC1.46
WACC8.82%
1SXP.DE Yearly LT Debt VS Equity VS FCF1SXP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • 1SXP has a Current Ratio of 1.58. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
  • 1SXP has a Current ratio (1.58) which is in line with its industry peers.
  • 1SXP has a Quick Ratio of 1.17. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
  • 1SXP has a better Quick ratio (1.17) than 61.90% of its industry peers.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.17
1SXP.DE Yearly Current Assets VS Current Liabilites1SXP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. 1SXP.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 12.36% over the past year.
  • 1SXP shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.78% yearly.
  • 1SXP shows a small growth in Revenue. In the last year, the Revenue has grown by 4.39%.
  • Measured over the past years, 1SXP shows a quite strong growth in Revenue. The Revenue has been growing by 11.04% on average per year.
EPS 1Y (TTM)12.36%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%15.79%
Revenue 1Y (TTM)4.39%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.5%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.01% on average over the next years. This is quite good.
  • 1SXP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.75% yearly.
EPS Next Y-1.71%
EPS Next 2Y6.04%
EPS Next 3Y8.07%
EPS Next 5Y8.01%
Revenue Next Year2.29%
Revenue Next 2Y4.62%
Revenue Next 3Y5.35%
Revenue Next 5Y5.75%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1SXP.DE Yearly Revenue VS Estimates1SXP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
1SXP.DE Yearly EPS VS Estimates1SXP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

5

4. 1SXP.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 13.76, which indicates a correct valuation of 1SXP.
  • 1SXP's Price/Earnings ratio is rather cheap when compared to the industry. 1SXP is cheaper than 90.48% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.91, 1SXP is valued a bit cheaper.
  • 1SXP is valuated correctly with a Price/Forward Earnings ratio of 12.61.
  • Based on the Price/Forward Earnings ratio, 1SXP is valued cheaply inside the industry as 90.48% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 23.69. 1SXP is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 13.76
Fwd PE 12.61
1SXP.DE Price Earnings VS Forward Price Earnings1SXP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 1SXP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1SXP is cheaper than 90.48% of the companies in the same industry.
  • 1SXP's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. 1SXP is more expensive than 61.90% of the companies in the same industry.
Industry RankSector Rank
P/FCF 174.49
EV/EBITDA 7.74
1SXP.DE Per share data1SXP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The decent profitability rating of 1SXP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1
EPS Next 2Y6.04%
EPS Next 3Y8.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. 1SXP.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 1.33%, 1SXP has a reasonable but not impressive dividend return.
  • 1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.45. 1SXP pays more dividend than 95.24% of the companies in the same industry.
  • 1SXP's Dividend Yield is slightly below the S&P500 average, which is at 1.89.
Industry RankSector Rank
Dividend Yield 1.33%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years2
Div Non Decr Years2
1SXP.DE Yearly Dividends per share1SXP.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 2026 0.05 0.1 0.15

5.3 Sustainability

  • 15.99% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP15.99%
EPS Next 2Y6.04%
EPS Next 3Y8.07%
1SXP.DE Yearly Income VS Free CF VS Dividend1SXP.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Dividend Payout.1SXP.DE Dividend Payout, showing the Payout Ratio.1SXP.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

1SXP.DE Fundamentals: All Metrics, Ratios and Statistics

SCHOTT PHARMA AG& CO KGAA

FRA:1SXP (4/9/2026, 5:29:22 PM)

13.76

+0.04 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-11
Earnings (Next)05-13
Inst Owners20.95%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.07B
Revenue(TTM)996.56M
Net Income(TTM)150.74M
Analysts76.84
Price Target19.93 (44.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.33%
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP15.99%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.69%
Min EPS beat(2)-3.5%
Max EPS beat(2)14.88%
EPS beat(4)2
Avg EPS beat(4)3.95%
Min EPS beat(4)-3.5%
Max EPS beat(4)14.88%
EPS beat(8)3
Avg EPS beat(8)2.57%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.32%
Min Revenue beat(2)-1.99%
Max Revenue beat(2)2.64%
Revenue beat(4)2
Avg Revenue beat(4)0.03%
Min Revenue beat(4)-2.27%
Max Revenue beat(4)2.64%
Revenue beat(8)3
Avg Revenue beat(8)0.09%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.81%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.81%
Valuation
Industry RankSector Rank
PE 13.76
Fwd PE 12.61
P/S 2.08
P/FCF 174.49
P/OCF 13.04
P/B 2.23
P/tB 2.3
EV/EBITDA 7.74
EPS(TTM)1
EY7.27%
EPS(NY)1.09
Fwd EY7.93%
FCF(TTM)0.08
FCFY0.57%
OCF(TTM)1.06
OCFY7.67%
SpS6.62
BVpS6.18
TBVpS5.98
PEG (NY)N/A
PEG (5Y)1
Graham Number11.79
Profitability
Industry RankSector Rank
ROA 9.26%
ROE 16.21%
ROCE 16.05%
ROIC 12.84%
ROICexc 13.2%
ROICexgc 13.55%
OM 19.08%
PM (TTM) 15.13%
GM 33.68%
FCFM 1.19%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
ROICexc(3y)15.01%
ROICexc(5y)16.12%
ROICexgc(3y)15.5%
ROICexgc(5y)16.82%
ROCE(3y)18.26%
ROCE(5y)19.44%
ROICexgc growth 3Y-6.05%
ROICexgc growth 5Y-8.67%
ROICexc growth 3Y-5.65%
ROICexc growth 5Y-7.55%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 7.05
Debt/EBITDA 0.29
Cap/Depr 178.66%
Cap/Sales 14.76%
Interest Coverage 13.03
Cash Conversion 58.33%
Profit Quality 7.88%
Current Ratio 1.58
Quick Ratio 1.17
Altman-Z N/A
F-Score7
WACC8.82%
ROIC/WACC1.46
Cap/Depr(3y)260.7%
Cap/Depr(5y)265.72%
Cap/Sales(3y)16.46%
Cap/Sales(5y)16.64%
Profit Quality(3y)27.05%
Profit Quality(5y)27.58%
High Growth Momentum
Growth
EPS 1Y (TTM)12.36%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%15.79%
EPS Next Y-1.71%
EPS Next 2Y6.04%
EPS Next 3Y8.07%
EPS Next 5Y8.01%
Revenue 1Y (TTM)4.39%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.5%
Revenue Next Year2.29%
Revenue Next 2Y4.62%
Revenue Next 3Y5.35%
Revenue Next 5Y5.75%
EBIT growth 1Y18.83%
EBIT growth 3Y3.6%
EBIT growth 5Y15.48%
EBIT Next Year36.02%
EBIT Next 3Y18.01%
EBIT Next 5Y13.81%
FCF growth 1Y-55.75%
FCF growth 3Y6.15%
FCF growth 5Y12.98%
OCF growth 1Y-19.95%
OCF growth 3Y-0.4%
OCF growth 5Y11.5%

SCHOTT PHARMA AG& CO KGAA / 1SXP.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?

ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.


What is the valuation status for 1SXP stock?

ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for SCHOTT PHARMA AG& CO KGAA?

SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 7 / 10.


What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?

The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to decline by -1.71% in the next year.


Is the dividend of SCHOTT PHARMA AG& CO KGAA sustainable?

The dividend rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 4 / 10 and the dividend payout ratio is 15.99%.